<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246086</url>
  </required_header>
  <id_info>
    <org_study_id>CO41942</org_study_id>
    <secondary_id>2019-004291-20</secondary_id>
    <nct_id>NCT04246086</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma</brief_title>
  <official_title>A Phase Ib, Open-Label, Non-Randomized, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab in Combination With Lenalidomide or Glofitamab in Combination With Lenalidomide or Glofitamab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of
      mosunetuzumab + lenalidomide, glofitamab + lenalidomide, and glofitamab + lenalidomide +
      obinutuzumab in participants with relapsed or refractory (R/R) follicular lymphoma (FL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 2 Days 2-21 (cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline to 90 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>Up to the end of Cycle 8 (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to the end of Cycle 8 (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, up to the end of Cycle 8 (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Reponse (DOCR)</measure>
    <time_frame>From the first occurrence of a documented complete response (CR) to disease progression, relapse, or death from any cause, whichever occurs first, up to the end of Cycle 8 (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration vs Time Curve (AUC) of Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of Glofitamab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Glofitamab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Glofitamab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through follow up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADAs) to Glofitamab</measure>
    <time_frame>At pre-defined intervals from baseline through follow-up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ADAs to Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from baseline through follow-up (2 years after last treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Mosunetuzumab + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment with mosunetuzumab for 8-12 cycles, plus lenalidomide for up to 12 total cycles (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glofitamab + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab for 8-12 cycles, plus lanalidomide for up to 12 total cycles (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glofitamab + Obinutuzumab + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab and obinutuzumab for 8-12 cycles, plus lenalidomide for up to 12 cycles (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glofitamab</intervention_name>
    <description>Participants will receive intravenous (IV) CD20-TCB as defined by the study protocol</description>
    <arm_group_label>Glofitamab + Lenalidomide</arm_group_label>
    <arm_group_label>Glofitamab + Obinutuzumab + Lenalidomide</arm_group_label>
    <other_name>RO7082859, CD20-TCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive IV mosunetuzumab as defined by the study protocol</description>
    <arm_group_label>Mosunetuzumab + Lenalidomide</arm_group_label>
    <other_name>RO7030816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Participants will receive IV obinutuzumab as defined by the study protocol</description>
    <arm_group_label>Glofitamab + Lenalidomide</arm_group_label>
    <arm_group_label>Glofitamab + Obinutuzumab + Lenalidomide</arm_group_label>
    <other_name>RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol</description>
    <arm_group_label>Glofitamab + Lenalidomide</arm_group_label>
    <arm_group_label>Glofitamab + Obinutuzumab + Lenalidomide</arm_group_label>
    <arm_group_label>Mosunetuzumab + Lenalidomide</arm_group_label>
    <other_name>RO4877533</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Participants will receive oral lenalidomide as defined by the study protocol</description>
    <arm_group_label>Glofitamab + Lenalidomide</arm_group_label>
    <arm_group_label>Glofitamab + Obinutuzumab + Lenalidomide</arm_group_label>
    <arm_group_label>Mosunetuzumab + Lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2

          -  R/R FL after treatment with at least one prior chemo immunotherapy regimen that
             included an anti CD20 monoclonal antibody (MAb) and for which no other more
             appropriate treatment option exists as determined by the investigator

          -  Histologically documented lymphoma that expresses CD20 at time of diagnosis as
             determined by the local laboratory

          -  Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive
             lymphoma)

          -  At least one bi dimensionally measurable nodal lesion (&gt;1.5 cm in its largest
             dimension by PET- computed tomography (CT) scan), or at least one bi dimensionally
             measurable extranodal lesion (&gt;1.0 cm in its largest dimension by PET-CT scan)

          -  Availability of a representative tumor specimen and the corresponding pathology report
             for confirmation of the diagnosis of FL

          -  Agreement to comply with all local requirements of the Len risk minimization plan

          -  For women of childbearing potential: agreement to remain abstinent or use two adequate
             methods of contraception, including at least one method with a failure rate of &lt; 1%
             per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period,
             and for at least 12 months after the final dose of glofitamab, 28 days after the last
             dose of Len, 18 months after the last dose of G, 3 months after the final dose of
             tocilizumab, and 3 months after the final dose of Mosun. Women must refrain from
             donating eggs during this same period

          -  For men: agreement to remain abstinent or use contraceptive measures and agreement to
             refrain from donating sperm, with female partners of childbearing potential or
             pregnant female partners, men must remain abstinent or use a condom during the
             treatment period and for at least 2 months after the final dose of glofitamab, 28 days
             after last dose of Len, 18 months after the last dose of G, 3 months after the final
             dose of tocilizumab, and 3 months after the final dose of Mosun

        Exclusion Criteria

          -  Grade 3b FL

          -  History of transformation of indolent disease to diffuse large B-cell lymphoma

          -  Documented refractoriness to an obinutuzumab monotherapy containing regimen in
             glofitamab-containing treatment combination

          -  Active or history of central nervous system lymphoma or leptomeningeal infiltration

          -  Prior standard or investigational anti-cancer therapy as specified

          -  Clinically significant toxicity (other than alopecia) from prior treatment that has
             not resolved to Grade &lt;=2 prior to Day 1 of Cycle 1

          -  Treatment with systemic immunosuppressive medications, including, but not limited to,
             prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor
             agents within 2 weeks prior to Day 1 of Cycle 1

          -  History of solid organ transplantation

          -  History of severe allergic or anaphylactic reaction to humanized, chimeric or murine
             MAbs

          -  Known sensitivity or allergy to murine products

          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
             or any component of the glofitamab, Mosun, G, Len, or thalidomide formulation,
             including mannitol

          -  History of erythema multiforme, Grade &gt;=3 rash, or blistering following prior
             treatment with immunomodulatory derivatives

          -  Known history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis or evidence of active pneumonitis on screening chest CT scan

          -  Known active bacterial, viral, fungal, or other infection, or any major episode of
             infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1

          -  Known or suspected chronic active Epstein-Barr virus infection or hemophagocytic
             syndrome

          -  Active Hepatitis B and Hepatitis C infection or autoimmune disease requiring treatment

          -  Known history of HIV positive status

          -  History of progressive multifocal leukoencephalopathy

          -  Administration of a live, attenuated vaccine within 4 weeks before first dose of study
             treatment or anticipation that such a live attenuated vaccine will be required during
             the study

          -  History of other malignancy that could affect compliance with the protocol or
             interpretation of results

          -  Contraindication to treatment for thromboembolism prophylaxis

          -  Grade &gt;=2 neuropathy

          -  Evidence of any significant, uncontrolled concomitant disease that could affect
             compliance with the protocol or interpretation of results, including, but not limited
             to significant cardiovascular disease or significant pulmonary disease

          -  Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of
             Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the
             study

          -  Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          -  Inadequate hematologic function

          -  Any of the following abnormal laboratory values

          -  Pregnant or lactating or intending to become pregnant during the study

          -  Life expectancy &lt; 3 months

          -  Unable to comply with the study protocol, in the investigator's judgment

          -  History of illicit drug or alcohol abuse within 12 months prior to screening, in the
             investigator's judgment

          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the
             investigator's or Medical Monitor's judgment, precludes the patient's safe
             participation in and completion of the study, or which could affect compliance with
             the protocol or interpretation of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: CO41942 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud; Direction Générale</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes cedex 09</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse -Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

